How could the collaboration with Medicare on new care models affect Eli Lilly and Company?
New Medicare care models may change how Eli Lilly is reimbursed The collaboration between the American Society of Nephrology and Medicare to develop new care models could alter the financial structure for pharmaceutical providers. Decisions being made in Washington regarding Medicare reimbursement and care delivery are noted to have lasting consequences for the nephrology specialty, which includes major pharmaceutical companies like Eli Lilly and Company. These new models could shift how services and treatments are paid for, potentially impacting revenue streams and operational costs for the company.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
The American Society of Nephrology is collaborating with Medicare to develop new care models. Samir M. Parikh, president of the American Society of Nephrology, called on nephrologists to engage in kidney health advocacy and innovation. ASN has been working to garner bipartisan support from decision-makers in Washington, D.C.
The full event1independent outlet -
The reports state that decisions being made in Washington regarding Medicare reimbursement and care delivery will have lasting consequences for the specialty. As a major pharmaceutical provider in the field, Eli Lilly and Company is subject to these changes in how treatments are funded and delivered.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- ASN is partnering with Medicare on new care models.healio.com
- Decisions being made in Washington about Medicare reimbursement and care delivery will have lasting consequences for the specialty.healio.com
Why it matters
For Eli Lilly and Company, the structure of Medicare reimbursement is critical to its revenue stability and market access. Changes to care delivery models could shift the financial incentives away from traditional fee-for-service payments toward value-based care, requiring the company to adapt its pricing and service delivery strategies.
This collaboration is part of a larger push by the American Society of Nephrology to influence policy and advocacy in Washington, D.C. The organization has focused on garnering bipartisan support for initiatives that affect kidney health, including the HHS Kidney Care National Plan.
What we don't know yet
- What specific reimbursement mechanisms are being discussed in the new care models?
- How will the new care models affect the coverage of specific pharmaceutical treatments?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- healio.comSaturday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.